Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
October 06 2021 - 7:30AM
Heat Biologics, Inc. (“Heat”)
(NASDAQ: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, today announced the
appointment of Paul Tebbey, Ph.D. as Senior Vice President of
Product Development and Portfolio Strategy.
Dr. Tebbey is a pharmaceutical development
strategy leader with over 25 years of healthcare and management
experience across the biotechnology and pharmaceutical sectors at
companies such as Abbvie, Baxter, Centocor/Johnson & Johnson
and Wyeth/Pfizer. Dr. Tebbey’s research, development and commercial
launch experiences include novel monoclonal antibodies (STELARA®
first-in-IL-12/23 class, REMICADE® & HUMIRA® anti-TNF mAbs),
complex vaccines (PREVNAR® novel conjugated vaccine, influenza and
respiratory syncytial virus), biosimilars as well as targeted
oncolytic small molecules (VENCLEXTA®). Dr. Tebbey received a Ph.D.
in Microbiology and Immunology from East Carolina University School
of Medicine where his research focused on T lymphocyte cell
signaling, immunosuppression and transformation and completed his
postdoctoral studies at Vanderbilt University focusing on the
regulation of gene expression. Dr. Tebbey’s publications include
over 40 peer-reviewed articles that span immunology,
immune-mediated and infectious diseases, clinical trial design as
well as pharmaceutical strategy planning and brand success.
Jeff Wolf, Chief Executive Officer of Heat,
commented, “Paul’s background and proven track record will help
advance our current and planned clinical programs, as well as our
extensive ongoing R&D and emerging biosecurity
initiatives.”
Paul Tebbey further noted, “I am excited to join
Heat Biologics at this exciting time. Heat has developed a robust
clinical platform spanning both oncology and infectious diseases.
On the R&D front, I look forward to helping advance numerous,
value-driving clinical programs as well as Skunkworx, which is
utilizing integrated computational and bioinformatic analysis with
the goal of accelerating the speed and reducing the costs
associated with drug development.”
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in a Phase 2 trial, various infectious
disease/biological threat programs in preclinical development and a
pipeline of proprietary immunomodulatory antibodies and cell-based
therapies, including PTX-35 and HS-130 in Phase 1 clinical
trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements regarding Dr. Tebbey’s background and proven track
record helping advance Heat’s current and planned clinical
programs, as well as its extensive ongoing R&D and emerging
biosecurity initiatives and Dr. Tebbey helping advance numerous,
value-driving clinical programs as well as Skunkworx, which is
utilizing integrated computational and bioinformatic analysis with
the goal of accelerating the speed and reducing the costs
associated with drug development. These statements are subject to a
number of risks and uncertainties, many of which are difficult to
predict, including the ability to successfully integrate Dr. Tebbey
into the management team and derive the anticipated contributions
from Dr. Tebbey, the ability of Heat's therapies to perform as
designed, to demonstrate safety and efficacy, as well as results
that are consistent with prior results, the ability to enroll
patients and complete the clinical trials on time and achieve
desired results and benefits, especially in light of COVID-19,
Heat's ability to obtain regulatory approvals for commercialization
of product candidates or to comply with ongoing regulatory
requirements, regulatory limitations relating to Heat's ability to
promote or commercialize its product candidates for specific
indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products, Heat's ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities and its cash and short-term investments
providing significant runway to fund Heat’s current clinical
programs and further expand Heat’s therapeutic portfolio , its
ability to continue to maintain its listing on the Nasdaq Capital
Market and its ability to retain its key scientists or management
personnel, and the other factors described in Heat's annual report
on Form 10-K for the year ended December 31, 2020 filed with the
SEC, and other subsequent filings with the SEC. The information in
this release is provided only as of the date of this release, and
Heat undertakes no obligation to update any forward-looking
statements contained in this release based on new information,
future events, or otherwise, except as required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024